BRIDGET: Preventing Secondary Brain Metastases in Advanced HER2+ Breast Cancer

Opinion
Video

Carey Anders, MD, offers insights into the BRIDGET trial, a study investigating the role of tucatinib in the prevention of secondary brain metastases in patients with advanced HER2-positive breast cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
4 experts in this video
4 experts in this video
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
4 experts in this video
Related Content